Precision Diets for Diabetes Prevention
2 other identifiers
interventional
100
1 country
1
Brief Summary
With this study the investigators want to understand the physiological differences for people developing pre-diabetes and diabetes. The investigators hypothesize that different individuals go through different paths in the development of the disease. By understanding the personal mechanism for developing disease, the investigators will find a personalized approach to prevent that development. The investigators are also hoping to be able to find a biomarker that will pinpoint to the particular defect and thus, diagnose the problem at an earlier stage and have the information to give personalized diet recommendations to prevent the development of diabetes more effectively.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started May 2018
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 24, 2018
CompletedFirst Submitted
Initial submission to the registry
December 20, 2018
CompletedFirst Posted
Study publicly available on registry
April 18, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2025
CompletedMay 25, 2025
May 1, 2025
7.5 years
December 20, 2018
May 23, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Change in glycemic control as measured by change blood sugar values
Change in glycemic control measured from baseline through all phases of study. Glycemic control is derived from continuous glucose monitor (CGM) data and expressed in milligrams/deciliter.
Three years
Classification of metabolic subphenotype
Classify metabolic subphenotype in individuals without diabetes using a machine learning algorithm applied to the glucose time-series response generated by a 16-point (blood draws) OGTT done in the clinical research center and at home (using CGM)
Four years
Secondary Outcomes (1)
Change in area under the curve (AUC) of blood glucose level
Three years
Study Arms (1)
Optimizing Diet for Glycemic Control
OTHERPhase 1: Metabolic testing will include 3 metabolic tests: 1. The Oral Glucose Tolerance Test. The participant will wear the CGM while undergoing the OGTT + will be asked to repeat the test at home twice. 2. The Insulin Sensitivity Test (Steady State Plasma Glucose). This test is designed to measure how well cells remove glucose from the blood in response to insulin. 3. The Isoglycemic Intravenous Glucose Infusion (IIGI). This test is designed to measure the incretin hormone effect. Phase 2: Participants follow their own diet while using the CGM. Participants are provided with 5-10 standardized foods to test during this phase. Phase 3: Participants are provided with additional standardized foods and counseled to continue their own diet during this phase. Phase 4: Participants are counseled on reducing or limiting the foods that caused glucose spikes and they are also counseled on macronutrient composition of their diet based on lipid profile.
Interventions
Dietary counseling based on results of CGM analyses.
Eligibility Criteria
You may qualify if:
- Be 18 years of age or older;
- Not be pregnant, if female;
You may not qualify if:
- Have major organ disease, hypertension defined as \>160/100, pregnant/lactating, diabetogenic medications, malabsorptive disorders like celiac sprue, others, heavy alcohol use, use of weight loss medications or specific diets, weight change \> 2 kg in the last three weeks, history of bariatric surgery.
- Any medical condition that physicians believe would interfere with study participation or evaluation of results.
- Mental incapacity a nd/or cognitive impairment on the part of the patient that would preclude adequate understanding of, or cooperation with, the study protocol.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Stanford University
Stanford, California, 94304, United States
Related Publications (1)
Park H, Metwally AA, Delfarah A, Wu Y, Perelman D, Mayer C, McGinity C, Rodgar M, Celli A, McLaughlin T, Mignot E, Snyder M. High-resolution lifestyle profiling and metabolic subphenotypes of type 2 diabetes. NPJ Digit Med. 2025 Jun 11;8(1):352. doi: 10.1038/s41746-025-01728-6.
PMID: 40500312DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Michael P Snyder, PhD
Stanford University
- PRINCIPAL INVESTIGATOR
Tracey McLaughlin, MD
Stanford University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chair, Genetics Department
Study Record Dates
First Submitted
December 20, 2018
First Posted
April 18, 2019
Study Start
May 24, 2018
Primary Completion
December 1, 2025
Study Completion
December 1, 2025
Last Updated
May 25, 2025
Record last verified: 2025-05